Patented in US, KR, CN
Applications
A. Gene/Cell Therapy Development (Targeting Promoter)
B. Antibody/Protein Therapy Development (Super Promoter)
Synthetic Promoter Technology
Technology
Home >
Technology >
Synthetic Promoter Technology
Patented in US, KR, CN
A. Gene/Cell Therapy Development (Targeting Promoter)
B. Antibody/Protein Therapy Development (Super Promoter)
Announcement of base date and shareholder list closure period setting.
In accordance with Article 354 of the Commercial Act and Article 19 of our company's Articles of Incorporation, voting rights are granted to the shareholders listed in the shareholder register as of February 2, 2023. We hereby announce the suspension of changes in the stockholders' register, such as stock transfer, registration of pledge, change and cancellation of trust property, and indication and cancellation of trust property from February 3, 2023 to February 4, 2023 to confirm the right shareholders.
January 18, 2023
#406 Cheongju SB Plaza, 194-25 Osongsaengmyeong 1-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do
CEO of Ropibio Co., Ltd. Sung Ho Hahm
Transfer agent, Lee Myeong-ho, president of Korea Securities Depository